Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2025)

Amylyx Pharmaceuticals has reported Research & Development over the past 5 years, most recently at $21.2 million for Q4 2025.

  • Quarterly results put Research & Development at $21.2 million for Q4 2025, down 7.33% from a year ago — trailing twelve months through Dec 2025 was $90.4 million (down 13.14% YoY), and the annual figure for FY2025 was $90.4 million, down 13.14%.
  • Research & Development for Q4 2025 was $21.2 million at Amylyx Pharmaceuticals, up from $19.9 million in the prior quarter.
  • Over the last five years, Research & Development for AMLX hit a ceiling of $44.9 million in Q4 2023 and a floor of $6.9 million in Q1 2021.
  • Median Research & Development over the past 5 years was $22.9 million (2022), compared with a mean of $23.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 212.7% in 2022 and later crashed 49.03% in 2024.
  • Amylyx Pharmaceuticals' Research & Development stood at $13.4 million in 2021, then skyrocketed by 70.32% to $22.8 million in 2022, then skyrocketed by 96.88% to $44.9 million in 2023, then tumbled by 49.03% to $22.9 million in 2024, then fell by 7.33% to $21.2 million in 2025.
  • The last three reported values for Research & Development were $21.2 million (Q4 2025), $19.9 million (Q3 2025), and $27.2 million (Q2 2025) per Business Quant data.